Supernus Announces Third Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St futures muted as investors monitor US-Iran negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Supernus Pharma (SUPN) Tops Q3 EPS by 44c, Revenues Beat; Raises FY20 Revenue Guidance Above Consensus
November 3, 2020 4:33 PM ESTSupernus Pharma (NASDAQ: SUPN) reported Q3 EPS of $0.74, $0.44 better than the analyst estimate of $0.30. Revenue for the quarter came in at $155.1 million versus the consensus estimate of $130.66 million.
Q3 2020 total revenues of $155.1 million, including net product sales of $152.1 million and royalty revenues of $3.0 millionQ3 2020... More